ClinicalTrials.gg
CompletedNCT00439738Updated May 16, 2017Results posted

Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

A Phase 4 interventional study of HCTZ + Amlodipine and Valsartan/HCTZ in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-05-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
412
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
45th of 139
412 · median 198
Started
2006
with 22 others
Phase 4
67 of 140
none open now
Registered
76th of 140
by date
Lead sponsor
19 of 140
Novartis Pharmaceuticals

Among the 140 studies testing valsartan in Hypertension, this one is the 45th largest by enrollment of the 139 interventional ones that give a count, is one of 23 that started in 2006, is one of 67 in phase 4, and was the 76th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure [MSSBP] >150 mmHg) patients.

03

Conditions studied

  • Hypertension

Keywords

  • Obesity, hypertension, valsartan/hydrochlorothiazide
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 40 years of age or older
  • Moderate or severe high blood pressure defined as systolic blood pressure (the top number) greater than or equal to 150 mmHg and diastolic blood pressure (the bottom number) less then 110 mmHg
  • Central (abdominal) obesity

Exclusion criteria

Exclusion Criteria:

  • Systolic blood pressure (the top number) greater than or equal to 180 mmHg and diastolic blood pressure (the bottom number) greater than or equal to 110 mmHg
  • Currently taking more then 3 medications to treat high blood pressure
  • Inability to stop all current blood pressure medications if any up to 4 weeks
  • History of Type 1 or Type 2 diabetes
  • History of stroke, mini-stroke () or heart attack within the last 6 months
  • History of or current diagnosis of congestive heart failure
  • History of cancer within the past 5 years with the exception of localized basal cell carcinoma or squamous cell carcinoma
  • Women who are pregnant or nursing
  • Alcohol or drug abuse within the last 2 years

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
412 participants (actual)

Study arms

  • Experimental
    valsartan/HCTZ

    Drug: Valsartan/HCTZ

  • Active comparator
    HCTZ +Amlodipine

    Drug: HCTZ + Amlodipine

Interventions

  • DrugHCTZ + Amlodipine

    Drug pages: Hydrochlorothiazide · Amlodipine

    * 12.5 mg HCTZ capsules * 25 mg HCTZ capsules * 5 mg amlodipine capsules * 10 mg amlodipine capsules

  • DrugValsartan/HCTZ

    Drug pages: Valsartan · Hydrochlorothiazide

    * 160 mg film-coated valsartan tablets * 320 mg film-coated valsartan tablets * 12.5 mg HCTZ capsules * 25 mg HCTZ capsules

06

What researchers measure

Primary outcomes

  1. Change in Mean Sitting Systolic Blood Pressure (MSSBP)

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change in Mean Sitting Diastolic Blood Pressure (MSDBP)

    Time frame: Baseline to Weeks 4, 8, 12 and 16

  2. Number of Patients Achieving Blood Pressure (BP) Control by Visit (< 140/90 mm Hg)

    Mean sitting systolic blood pressure/mean sitting diastolic blood pressure \< 140/90 mm Hg

    Time frame: Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)

  3. Number of Patients Achieving Blood Pressure (BP)Control by Visit (< 130/80 mm Hg)

    Mean sitting systolic blood pressure/mean sitting diastolic blood pressure \< 130/80 mm Hg

    Time frame: Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)

  4. Change From Baseline in Postprandial Glucose

    After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test

    Time frame: Week 16

  5. Change From Baseline in Postprandial Insulin

    After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test

    Time frame: Week 16

  6. Change From Baseline in Postprandial Non-esterified Fatty Acids

    After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test

    Time frame: Week 16

07

Results

Posted Feb 10, 2009

Participant flow

Participant flow — Overall Study
MilestoneValsartan/HCTZ (Hydrochlorothiazide)HCTZ +Amlodipine
Started206206
Completed170178
Not completed3628
Withdrew: Withdrawal by subject1613
Withdrew: Adverse event64
Withdrew: Lost to follow-up56
Withdrew: Protocol violation63
Withdrew: Lack of efficacy22
Withdrew: Abnormal lab values10

Outcome measures

PrimaryChange in Mean Sitting Systolic Blood Pressure (MSSBP)
Time frame:
Baseline to Week 8
Reported as:
Mean · mm Hg
Change in Mean Sitting Systolic Blood Pressure (MSSBP)
mm HgValsartan/HCTZ (Hydrochlorothiazide)HCTZ +Amlodipine
Baseline159.7 ± 7.81159.0 ± 7.62
Week 8131.2 ± 16.26137.5 ± 13.52
Change from baseline-28.6 ± 15.61-21.5 ± 12.58
SecondaryChange in Mean Sitting Diastolic Blood Pressure (MSDBP)
Time frame:
Baseline to Weeks 4, 8, 12 and 16
Reported as:
Mean · mm Hg
Change in Mean Sitting Diastolic Blood Pressure (MSDBP)
mm HgValsartan/HCTZ (Hydrochlorothiazide)HCTZ +Amlodipine
Baseline94.9 ± 7.9493.6 ± 8.18
Week 485.7 ± 9.3887.6 ± 9.20
Week 881.9 ± 9.8785.1 ± 8.54
Week 1281.1 ± 9.1482.8 ± 8.75
Week 1680.8 ± 10.1480.9 ± 8.66
Change from baseline to week 16-14.0 ± 9.90-12.7 ± 8.35
SecondaryNumber of Patients Achieving Blood Pressure (BP) Control by Visit (< 140/90 mm Hg)

Mean sitting systolic blood pressure/mean sitting diastolic blood pressure \< 140/90 mm Hg

Time frame:
Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)
Reported as:
Number · participants
Number of Patients Achieving Blood Pressure (BP) Control by Visit (< 140/90 mm Hg)
participantsValsartan/HCTZ (Hydrochlorothiazide)HCTZ +Amlodipine
Week 49169
Week 8123102
Week 12122112
Week 16124140
End of study133146
SecondaryNumber of Patients Achieving Blood Pressure (BP)Control by Visit (< 130/80 mm Hg)

Mean sitting systolic blood pressure/mean sitting diastolic blood pressure \< 130/80 mm Hg

Time frame:
Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)
Reported as:
Number · participants
Number of Patients Achieving Blood Pressure (BP)Control by Visit (< 130/80 mm Hg)
participantsValsartan/HCTZ (Hydrochlorothiazide)HCTZ +Amlodipine
Week 43318
Week 85923
Week 125746
Week 166265
End of Study6868
SecondaryChange From Baseline in Postprandial Glucose

After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test

Time frame:
Week 16
Reported as:
Mean · mg/dL
Change From Baseline in Postprandial Glucose
mg/dLValsartan/HCTZ (Hydrochlorothiazide)HCTZ +Amlodipine
Baseline visit (0 minutes)98.0 ± 15.9199.4 ± 19.12
Week 16 (0 minutes)98.1 ± 15.68102.8 ± 17.81
Change from baseline to week 16 (0 minutes)-0.5 ± 13.713.4 ± 18.28
Baseline visit (120 minutes)123.9 ± 47.18127.7 ± 40.30
Week 16 (120 minutes)126.3 ± 49.52146.5 ± 56.51
Change from baseline to week 16 (120 minutes)2.1 ± 38.2118.9 ± 40.88
SecondaryChange From Baseline in Postprandial Insulin

After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test

Time frame:
Week 16
Reported as:
Mean · mg/dL
Change From Baseline in Postprandial Insulin
mg/dLValsartan/HCTZ (Hydrochlorothiazide)HCTZ +Amlodipine
Baseline visit (0 minutes)19.66 ± 20.43520.37 ± 20.583
Week 16 (0 minutes)23.45 ± 26.03923.62 ± 19.267
Change from baseline to week 16 (0 minutes)3.41 ± 28.4273.67 ± 19.170
Baseline visit (120 minutes)92.04 ± 82.18395.95 ± 76.483
Week 16 (120 minutes)116.04 ± 129.880120.01 ± 100.302
Change from baseline to week 16 (120 minute)24.68 ± 90.09428.07 ± 71.674
SecondaryChange From Baseline in Postprandial Non-esterified Fatty Acids

After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test

Time frame:
Week 16
Reported as:
Mean · mg/dL
Change From Baseline in Postprandial Non-esterified Fatty Acids
mg/dLValsartan/HCTZ (Hydrochlorothiazide)HCTZ +Amlodipine
Baseline visit (0 minutes)0.45 ± 0.2080.47 ± 0.318
Week 16 (0 minutes)0.46 ± 0.1940.47 ± 0.196
Change from baseline to week 16 (0 minutes)0.01 ± 0.2490.00 ± 0.341
Baseline visit (120 minutes)0.11 ± 0.0900.10 ± 0.116
Week 16 (120 minutes)0.10 ± 0.0930.10 ± 0.056
Change from baseline to week 16 (120 minutes)-0.01 ± 0.117-0.01 ± 0.120

Baseline characteristics

Age, Customized
Age, Customized(participants)Valsartan/HCTZ (Hydrochlorothiazide)HCTZ +AmlodipineTotal
< 65 years172 ± 83.5180 ± 87.4352 ± 85.4
>=65 years34 ± 16.526 ± 12.660 ± 14.6
Sex: Female, Male
Sex: Female, Male(Participants)Valsartan/HCTZ (Hydrochlorothiazide)HCTZ +AmlodipineTotal
Female124148272
Male8258140
08

Study locations

5 sites
  • Terence T. Hart, MD
    Muscle Shoals, Alabama 35662, United States
  • Westlake Medical Research
    Westlake Village, California 91361, United States
  • Oklahoma Cardiovascular & Hypertension
    Oklahoma City, Oklahoma 73132, United States
  • Northeast Tarrant Internal Medicine Assoc
    Euless, Texas 76040, United States
  • Frandsen Family Medicine
    Port Orchard, Washington 98366, United States
09

References and documents

Publications

  • Deedwania PC, Zappe DH, Egan BM, Purkayastha D, Samuel R, Sowers JR. Does response of RAS blockade on serum K+ levels influence its glycemic-mitigating response when combined with hydrochlorothiazide? J Clin Hypertens (Greenwich). 2012 Jul;14(7):415-21. doi: 10.1111/j.1751-7176.2012.00635.x. Epub 2012 Apr 26. PubMed 22747613 ↗
  • Ofili EO, Zappe DH, Purkayastha D, Samuel R, Sowers JR. Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients. Am J Ther. 2013 Jan;20(1):2-12. doi: 10.1097/MJT.0b013e318230ae66. PubMed 22248871 ↗
  • Sowers JR, Raij L, Jialal I, Egan BM, Ofili EO, Samuel R, Zappe DH, Purkayastha D, Deedwania PC. Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. J Hypertens. 2010 Aug;28(8):1761-9. doi: 10.1097/HJH.0b013e32833af380. PubMed 20498618 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006 and a primary completion of Nov 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2007
First posted
Feb 26, 2007
Start
Dec 2006
Primary completionActual
Nov 2007
Results first posted
Feb 10, 2009
Last update
May 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00439738
First posted
Feb 26, 2007
Start date
Dec 2006
Primary completion
Nov 2007
Results posted
Feb 10, 2009
Last update
May 16, 2017

Study contacts

Novartis Pharmaceuticals
study chair · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valsartan · Hydrochlorothiazide

Start the discussion